Abstract
Identification of novel risk biomarkers may enhance early detection of smoking-related lung cancer. We measured 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia.
We identified 36 proteins with replicable associations with risk of imminent lung cancer diagnosis (all p<4×10-5). These included several documented tumor markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) but most had not been previously reported. The 36 proteins included several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation ranged from 1.31 for IGFBP-1 (95% CI: 1.17-1.47) to 2.43 for CEACAM5 (95% CI: 2.04-2.89). We mapped the 36 proteins to the hallmarks of cancer and found that proliferative signaling, tumor-promoting inflammation, and activation of invasion and metastasis were most frequently implicated.
Statement of significance After screening 1,162 proteins, we identified 36 markers of imminent smoking-related lung cancer diagnosis with a wide range of functions and relevance across the hallmarks of cancer. Forthcoming studies will address the extent to which these markers can discriminate future lung cancer cases and their utility for early detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the US NCI (INTEGRAL program U19 CA203654 and R03 CA245979), Fondation ARC pour la recherche sur le cancer and l'Institut National du Cancer (INCa) (INCA201601246/ARC_10450, Fondation ARC et INCa, France), INCa (TABAC18-035, France), the Cancer Research Foundation of Northern Sweden (AMP19-962), an early detection of cancer development grant from Swedish Department of Health ministry, and Cancer Research UK [C18281/A29019]. RJH is supported by the Canada Research Chair of the Canadian Institute of Health Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IARC's (International Agency for Research on Cancer) ethics committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos